Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2001-10-4
pubmed:abstractText
The 1990s have seen the emergence of several classes of new efficacious drugs which have become established as treatment for breast cancer. Thus, aromatase inhibitors, taxanes and herceptin have all emerged as potentially valuable therapeutic agents for treatment of advanced breast cancer. Bisphosphonates have found a place in preventing skeletal complications in breast cancer patients with bone metastasis. Tamoxifen has a new role in chemoprevention in patients at high risk of breast cancer. This paper summarises these results.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anthracyclines, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal, http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Bridged Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Estrogens, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen, http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen, http://linkedlifedata.com/resource/pubmed/chemical/Taxoids, http://linkedlifedata.com/resource/pubmed/chemical/taxane, http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1465-6566
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
975-85
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11585013-Anthracyclines, pubmed-meshheading:11585013-Antibodies, Monoclonal, pubmed-meshheading:11585013-Antibodies, Monoclonal, Humanized, pubmed-meshheading:11585013-Antineoplastic Agents, Hormonal, pubmed-meshheading:11585013-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11585013-Aromatase Inhibitors, pubmed-meshheading:11585013-Breast Neoplasms, pubmed-meshheading:11585013-Bridged Compounds, pubmed-meshheading:11585013-Chemotherapy, Adjuvant, pubmed-meshheading:11585013-Cholesterol, pubmed-meshheading:11585013-Clinical Trials as Topic, pubmed-meshheading:11585013-Diphosphonates, pubmed-meshheading:11585013-Estrogens, pubmed-meshheading:11585013-Female, pubmed-meshheading:11585013-Guidelines as Topic, pubmed-meshheading:11585013-Humans, pubmed-meshheading:11585013-Neoplasm Metastasis, pubmed-meshheading:11585013-Postmenopause, pubmed-meshheading:11585013-Receptors, Estrogen, pubmed-meshheading:11585013-Tamoxifen, pubmed-meshheading:11585013-Taxoids
pubmed:year
2001
pubmed:articleTitle
New drugs in breast cancer.
pubmed:affiliation
Breast Unit Research Group, Western General Hospital, Edinburgh, UK.
pubmed:publicationType
Journal Article, Review